PT - JOURNAL ARTICLE AU - Fyles, Martyn AU - Mellor, Jonathon AU - Paton, Robert AU - Overton, Christopher E. AU - Phillips, Alexander M. AU - Glaser, Alex AU - Ward, Thomas TI - The Incidence and Prevalence of SARS-CoV-2 in the UK Population from the UKHSA Winter COVID Infection Study AID - 10.1101/2024.10.23.24315984 DP - 2024 Jan 01 TA - medRxiv PG - 2024.10.23.24315984 4099 - http://medrxiv.org/content/early/2024/10/23/2024.10.23.24315984.short 4100 - http://medrxiv.org/content/early/2024/10/23/2024.10.23.24315984.full AB - The SARS-CoV-2 virus continues to cause substantial morbidity and mortality, particularly during the winter period. The Winter Covid Infection Study (WCIS) ran from the 14th of November 2023 to the 7th of March 2024, and enabled the UK Health Security Agency to publish fortnightly estimates of the incidence and prevalence of SARS-CoV-2. Testing was performed using Lateral Flow Devices (LFD), and a repeat testing design was used to estimate key epidemiological parameters of SARS-CoV-2. This facilitated the estimation of time-varying prevalence, incidence, and test sensitivity. A Bayesian multilevel regression and poststratification model was developed to produce representative and unbiased estimates. In England and Scotland, prevalence peaked at 4.54% (95% CI: 3.90 to 5.24), and incidence peaked at 498 (95% CrI: 429 to 585) new infections per 100,000 individuals per day. The average LFD test sensitivity in England and Scotland during the study was estimated to be 72.1% (95% CrI: 70.3, 74.0), though due to epidemic phase bias this varied from a minimum value of 68.6% (95% CrI: 66.4 to 70.7) to a maximum value of 77.2% (95% CrI: 75.3 to 79.2). The novel study design of WCIS addressed key survey design challenges faced by previous large-scale SARS-CoV-2 population prevalence studies. The study demonstrated the utility and cost-benefit of LFD tests in large community surveys of prevalence.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThere was no financial support for this work, completed as part of the authors employment.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:National Statisticians Data Ethics Advisory Committee of UK Statistics Authority gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesUKHSA operates a robust governance process for applying to access protected data that considers: the benefits and risks of how the data will be used; compliance with policy, regulatory and ethical obligations; data minimisation; how the confidentiality, integrity, and availability will be maintained; retention, archival, and disposal requirements; best practice for protecting data, including the application of 'privacy by design and by default', emerging privacy conserving technologies and contractual controls Access to protected data is always strictly controlled using legally binding data sharing contracts. UKHSA welcomes data applications from organisations looking to use protected data for public health purposes. To request an application pack or discuss a request for UKHSA data you would like to submit, contact DataAccess@ukhsa.gov.uk.